Advances and Challenges in Immunotherapy of Small Cell Lung Cancer

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2020 Mar 21

PMID 32194311

Citations 18

Authors

Hanfei Guo

Lingyu Li

Jiuwei Cui

Affiliations

Soon will be listed here.

Abstract

Small cell lung cancer (SCLC) is a highly lethal disease, characterized by early metastasis and rapid growth, and no effective treatment after relapse. Etoposide-platinum (EP) combination has been the backbone therapy of SCLC over the past 30 years. It is extremely urgent and important to seek new therapies for SCLC. In the past 5 years, immunotherapy, such as immune checkpoint inhibitors programmed cell death protein-1 (PD-1), cytotoxic T lymphocyte associatedprotein-4 (CTLA-4), has made remarkable achievements in the treatment of patients with SCLC, and it has become the first-line option for the treatment of some patients. Some traditional chemotherapeutic drugs or targeted drugs, such as alkylating agent temozolomide and transcription inhibitor lurbinectedin, have been found to have immunomodulatory effects and are expected to become new immunotherapeutic agents. In this study, we aimed to review the efficacy of new treatments for SCLC and discuss the current challenges and application prospect in the treatment of SCLC patients.

Citing Articles

[Immunotherapy for Extensive-stage Small Cell Lung Cancer:  Research Progress and Future Perspectives].

Zhong Y, Wang J, Wu L Zhongguo Fei Ai Za Zhi. 2025; 27(11):855-863.

PMID: 39800481 PMC: 11732389. DOI: 10.3779/j.issn.1009-3419.2024.102.35.

Photonanozyme-Kras-ribosome combination treatment of non-small cell lung cancer after COVID-19.

Si Q, Bai M, Wang X, Wang T, Qin Y Front Immunol. 2024; 15:1420463.

PMID: 39308869 PMC: 11412844. DOI: 10.3389/fimmu.2024.1420463.

Current Immunotherapy Treatments of Primary Breast Cancer Subtypes.

Brown S, Vomhof-DeKrey E Biomedicines. 2024; 12(4).

PMID: 38672249 PMC: 11048522. DOI: 10.3390/biomedicines12040895.

Non-Coding RNAs as Key Regulators in Lung Cancer.

Gilyazova I, Gimalova G, Nizamova A, Galimova E, Ishbulatova E, Pavlov V Int J Mol Sci. 2024; 25(1).

PMID: 38203731 PMC: 10778604. DOI: 10.3390/ijms25010560.

Radiotherapy and Immunotherapy in Lung Cancer.

Hsieh K, Dickstein D, Runnels J, Lehrer E, Rosenzweig K, Hirsch F Biomedicines. 2023; 11(6).

PMID: 37371737 PMC: 10295589. DOI: 10.3390/biomedicines11061642.

References

Rudin C, Giaccone G, Ismaila N . Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Oncol Pract. 2018; 12(1):83-86. DOI: 10.1200/JOP.2015.008201. View

Iclozan C, Antonia S, Chiappori A, Chen D, Gabrilovich D . Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013; 62(5):909-18. PMC: 3662237. DOI: 10.1007/s00262-013-1396-8. View

Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum R . Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014; 124(2):687-95. PMC: 3904601. DOI: 10.1172/JCI67313. View

Foy V, Schenk M, Baker K, Gomes F, Lallo A, Frese K . Targeting DNA damage in SCLC. Lung Cancer. 2017; 114:12-22. DOI: 10.1016/j.lungcan.2017.10.006. View

Savage P, Leventhal D, Malchow S . Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev. 2014; 259(1):245-58. PMC: 4122093. DOI: 10.1111/imr.12166. View

Antonia S, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N . Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006; 12(3 Pt 1):878-87. DOI: 10.1158/1078-0432.CCR-05-2013. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Golubovskaya V, Berahovich R, Zhou H, Xu S, Harto H, Li L . CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. Cancers (Basel). 2017; 9(10). PMC: 5664078. DOI: 10.3390/cancers9100139. View

Gong L, Zhou X, Yang J, Jiang Y, Yang H . Effects of the regulation of polysialyltransferase ST8SiaII on the invasiveness and metastasis of small cell lung cancer cells. Oncol Rep. 2016; 37(1):131-138. DOI: 10.3892/or.2016.5279. View

10.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

11.

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

12.

Byers L, Wang J, Nilsson M, Fujimoto J, Saintigny P, Yordy J . Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012; 2(9):798-811. PMC: 3567922. DOI: 10.1158/2159-8290.CD-12-0112. View

13.

Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C . Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. 2013; 134(2):342-51. DOI: 10.1002/ijc.28372. View

14.

Owonikoko T, Dahlberg S, Sica G, Wagner L, Wade 3rd J, Srkalovic G . Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol. 2018; 37(3):222-229. PMC: 6338394. DOI: 10.1200/JCO.18.00264. View

15.

Huang J, Kan Q, Lan , Zhao X, Zhang Z, Yang S . Chemotherapy in combination with cytokine-induced killer cell transfusion: An effective therapeutic option for patients with extensive stage small cell lung cancer. Int Immunopharmacol. 2017; 46:170-177. DOI: 10.1016/j.intimp.2016.12.005. View

16.

Ott P, Elez E, Hiret S, Kim D, Morosky A, Saraf S . Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017; 35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069. View

17.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

18.

Yuan J, Hegde P, Clynes R, Foukas P, Harari A, Kleen T . Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016; 4:3. PMC: 4717548. DOI: 10.1186/s40425-016-0107-3. View

19.

Ready N, Ott P, Hellmann M, Zugazagoitia J, Hann C, De Braud F . Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. J Thorac Oncol. 2019; 15(3):426-435. DOI: 10.1016/j.jtho.2019.10.004. View

20.

Heinzerling L, Ott P, Hodi F, Husain A, Tajmir-Riahi A, Tawbi H . Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016; 4:50. PMC: 4986340. DOI: 10.1186/s40425-016-0152-y. View